Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

(2011) MJ van den Bent et al.   LANCET ONCOLOGY

Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas

(2010) M. Peyre et al.   NEURO-ONCOLOGY

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

(2010) W. Taal et al.   NEURO-ONCOLOGY

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Recent Insights into PDGF-Induced Gliomagenesis

(2009) Filippo Calzolari et al.   BRAIN PATHOLOGY

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas

(2009) O Martinho et al.   BRITISH JOURNAL OF CANCER

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme

(2009) Matthias Holdhoff et al.   JOURNAL OF NEURO-ONCOLOGY

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

(2009) Gregor Dresemann et al.   JOURNAL OF NEURO-ONCOLOGY

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up

(2009) Linda Douw et al.   LANCET NEUROLOGY

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults

(2008) S. Kesari et al.   CLINICAL CANCER RESEARCH

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

(2008) Justin S. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

(2008) A. Tosoni et al.   JOURNAL OF NEURO-ONCOLOGY

Preoperative prognostic classification system for hemispheric low-grade gliomas in adults

(2008) Edward F. Chang et al.   JOURNAL OF NEUROSURGERY